Aldeyra Therapeutics Plunges 7.04% Amid Fraud Probe, Downgrade

Aldeyra Therapeutics experienced a significant drop of 7.04% in pre-market trading on May 6, 2025, raising concerns among investors about the company's recent developments and future prospects.

Pomerantz LLP has initiated an investigation into potential securities fraud or other unlawful business practices involving Aldeyra Therapeutics. This investigation comes in the wake of regulatory uncertainty and recent market volatility, which have impacted investor confidence in the company. The firm is advising investors to contact them for further information and potential legal action.

On April 2, 2025, Deutsche Bank downgraded Aldeyra Therapeutics from "Buy" to "Hold," citing regulatory uncertainty and potential patent infringement issues. This downgrade has contributed to the recent decline in the company's stock price, as investors reassess their positions in light of these new developments.